Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia Gabrail Cancer Research Center, Canton, Ohio Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee Belgium
Institut Jules Bordet, Anderlecht France
APHP de Marseille - Hôpital Nord, Marseille Institut de Cancerologie de Ouest (ICO) - Saint-Herblain, Saint-Herblain Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Gustave Roussy, Villejuif Germany
Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO), Cologne Universitätsklinikum Carl Gustav Carus Dresden, Dresden Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam South Korea
Yonsei University College of Medicine, Seoul Asan Medical Center (AMC), Seoul Spain
Hospital Universitario 12 de Octubre, Madrid Hospital Universitario La Paz, Madrid Taiwan
National Taiwan University Hospital, Taipei Taipei Medical University Hospital, Taipei Taipei Veterans General Hospital, Taipei